Lucid Diagnostics Stock Filter Stocks by Fundamentals
| LUCD Stock | USD 0.79 0.02 2.60% |
Lucid Diagnostics fundamentals help investors to digest information that contributes to Lucid Diagnostics' financial success or failures. It also enables traders to predict the movement of Lucid Stock. The fundamental analysis module provides a way to measure Lucid Diagnostics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lucid Diagnostics stock.
Lucid | Shares Owned by Institutions |
Lucid Diagnostics Institutional Holders
Institutional Holdings refers to the ownership stake in Lucid Diagnostics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Lucid Diagnostics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Lucid Diagnostics' value.| Shares | Virtu Financial Llc | 2024-06-30 | 14.2 K | Northern Trust Corp | 2024-09-30 | 13.1 K | First Manhattan Co. Llc | 2024-09-30 | 12.6 K | Resources Investment Advisors Inc | 2024-09-30 | 11.2 K | Byrne Asset Management Llc | 2024-06-30 | 11 K | Tower Research Capital Llc | 2024-09-30 | 6.1 K | Advisor Group Holdings, Inc. | 2024-09-30 | 3.1 K | Wells Fargo & Co | 2024-09-30 | 2.5 K | Jones Financial Companies Lllp | 2024-09-30 | 1.9 K | Luminus Management, Llc | 2024-09-30 | 1.2 M | Vanguard Group Inc | 2024-09-30 | 560.9 K |
Lucid Fundamentals
| Return On Equity | -10.08 | ||||
| Return On Asset | -1.01 | ||||
| Operating Margin | (9.98) % | ||||
| Current Valuation | 101.1 M | ||||
| Shares Outstanding | 59.34 M | ||||
| Shares Owned By Insiders | 60.83 % | ||||
| Shares Owned By Institutions | 4.18 % | ||||
| Number Of Shares Shorted | 421.84 K | ||||
| Price To Book | 2.16 X | ||||
| Price To Sales | 11.13 X | ||||
| Revenue | 2.43 M | ||||
| Gross Profit | (3.24 M) | ||||
| EBITDA | (49.75 M) | ||||
| Net Income | (52.67 M) | ||||
| Cash And Equivalents | 34.46 M | ||||
| Cash Per Share | 0.89 X | ||||
| Total Debt | 15.26 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 4.55 X | ||||
| Book Value Per Share | (0.96) X | ||||
| Cash Flow From Operations | (32.82 M) | ||||
| Short Ratio | 0.80 X | ||||
| Earnings Per Share | (1.12) X | ||||
| Target Price | 3.5 | ||||
| Number Of Employees | 70 | ||||
| Beta | 1.42 | ||||
| Market Capitalization | 46.61 M | ||||
| Total Asset | 27.27 M | ||||
| Retained Earnings | (150.74 M) | ||||
| Working Capital | (7.31 M) | ||||
| Net Asset | 27.27 M |
About Lucid Diagnostics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lucid Diagnostics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lucid Diagnostics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lucid Diagnostics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Lucid Diagnostics is a strong investment it is important to analyze Lucid Diagnostics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Lucid Diagnostics' future performance. For an informed investment choice regarding Lucid Stock, refer to the following important reports:Check out Lucid Diagnostics Piotroski F Score and Lucid Diagnostics Altman Z Score analysis. For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lucid Diagnostics. If investors know Lucid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lucid Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.12) | Revenue Per Share 0.09 | Quarterly Revenue Growth 0.497 | Return On Assets (1.01) | Return On Equity (10.08) |
The market value of Lucid Diagnostics is measured differently than its book value, which is the value of Lucid that is recorded on the company's balance sheet. Investors also form their own opinion of Lucid Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Lucid Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lucid Diagnostics' market value can be influenced by many factors that don't directly affect Lucid Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lucid Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lucid Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lucid Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.